Sprycel (dasatinib) is a prescription targeted therapy used to treat adults and children (1 year and older) with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). It works as a tyrosine kinase inhibitor, stopping the growth of cancer cells, especially when other treatments like imatinib have failed or cannot be tolerated.
